Sharpless, the founder of HealthSpan Dx, was trained in internal medicine at the Massachusetts General Hospital, and hematology and oncology at the Dana-Farber Cancer Institute, both at Harvard Medical School. He is currently the Wellcome Distinguished Professor of Cancer Research at the University of North Carolina at Chapel Hill, where he is also the Director of the Lineberger Comprehensive Cancer Center. He has authored more than 100 papers and book chapters as well as 10 patents on the molecular biology of cancer and aging. His research lab discovered the beneficial effects of Pharmacological Quiescence (PQ™) with regard to protection from DNA damaging agents. He is on the scientific advisory board of several scientific foundations, is Deputy Editor of the Journal of Clinical Investigation and serves as an elected council member of the American Society of Clinical Investigation, the nation’s oldest honor society for physician-scientists.
Natalia Mitin, PhD has over 15 years of experience in various research areas of life sciences. She has a strong background in molecular biology, biochemistry and cellular biology. In the last 10 years, Dr. Mitin held a research faculty position in the Department of Pharmacology at UNC Chapel Hill. During her tenure at UNC, Dr. Mitin trained and supervised research personnel, set up and managed collaborations, and procured funding. After leaving UNC, Natalia joined HealthSpan Dx where she led all assay development efforts and clinical collaborations, solicited non-dilutive funding, and managed day to day operations and business development opportunities.